Literature DB >> 16647442

FTY720 for treatment of ischemia-reperfusion injury following complete renal ischemia in C57/BL6 mice.

C P Kaudel1, U Schmiddem, M Frink, S Bergmann, H-C Pape, C Krettek, J Klempnauer, M Winkler.   

Abstract

BACKGROUND: Organ dysfunction followed by single-organ or even multiorgan failure due to ischemia-reperfusion injury (I/RI) is a common problem in liver and heart transplantation. Various approaches had been attempted to prevent this I/RI. One is the administration of FTY720, a synthetic structural analogue of sphingosine, which induces T-lymphocyte homing with consecutive lymphopenia. The purpose of this study was to evaluate the effect of intraoperative FTY720 administration following controlled bilateral kidney ischemia in comparison to steroid or placebo application.
METHODS: Male c57BL6/J mice (n = 115; body weight 25 to 30 g) received either FTY720 (1 mg/kg body weight) or steroids or saline solution. Ischemia was applied for 30 or 60 minutes with subsequent follow-up for 48 hours. At termination all surviving animals were sacrificed.
RESULTS: Following 30 minutes of ischemia, FTY720, but neither steroid nor vehicle treatment showed significant protective effects on long-term survival after controlled bilateral warm kidney ischemia. Fluorescein-activated cell sorting (FACS) analysis showed a significant T-lymphocyte depletion in peripheral blood after FTY720 treatment, which was not observed after steroid or vehicle treatment.
CONCLUSION: The improved long-term survival shown in this study might be due to a protective effect of FTY720 to prevent I/RI, which may be mediated by the lymphocyte depletion shown in the FACS analysis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16647442     DOI: 10.1016/j.transproceed.2006.01.033

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  8 in total

1.  Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury.

Authors:  Amandeep Bajwa; Sang-Kyung Jo; Hong Ye; Liping Huang; Krishna R Dondeti; Diane L Rosin; Volker H Haase; Timothy L Macdonald; Kevin R Lynch; Mark D Okusa
Journal:  J Am Soc Nephrol       Date:  2010-03-25       Impact factor: 10.121

Review 2.  Ischemia-reperfusion and immediate T cell responses.

Authors:  Yanfei Huang; Hamid Rabb; Karl L Womer
Journal:  Cell Immunol       Date:  2007-10-17       Impact factor: 4.868

Review 3.  The influence of sphingosine-1-phosphate receptor signaling on lymphocyte trafficking: how a bioactive lipid mediator grew up from an "immature" vascular maturation factor to a "mature" mediator of lymphocyte behavior and function.

Authors:  Michael D Davis; John H Kehrl
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

4.  Pharmacological pre- and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischaemia-reperfusion.

Authors:  U Hofmann; K Hu; F Walter; N Burkard; G Ertl; J Bauersachs; O Ritter; S Frantz; A Bonz
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 5.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

Review 6.  Lymphocytes and ischemia-reperfusion injury.

Authors:  Douglas Linfert; Tayseer Chowdhry; Hamid Rabb
Journal:  Transplant Rev (Orlando)       Date:  2009-01       Impact factor: 3.943

7.  S1P1 receptor modulation preserves vascular function in mesenteric and coronary arteries after CPB in the rat independent of depletion of lymphocytes.

Authors:  Iryna V Samarska; Hjalmar R Bouma; Hendrik Buikema; Hubert E Mungroop; Martin C Houwertjes; Anthony R Absalom; Anne H Epema; Robert H Henning
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

8.  FTY720 Regulates Mitochondria Biogenesis in Dendritic Cells to Prevent Kidney Ischemic Reperfusion Injury.

Authors:  Thomas V Rousselle; Canan Kuscu; Cem Kuscu; Kailo Schlegel; LiPing Huang; Maria Namwanje; James D Eason; Liza Makowski; Daniel Maluf; Valeria Mas; Amandeep Bajwa
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.